| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |